Compare UBSI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBSI | CRSP |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.0B |
| IPO Year | 1994 | 2016 |
| Metric | UBSI | CRSP |
|---|---|---|
| Price | $47.74 | $58.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 17 |
| Target Price | $43.17 | ★ $70.29 |
| AVG Volume (30 Days) | 857.0K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 18.91 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $311,957,000.00 | $289,590,000.00 |
| Revenue This Year | $10.13 | $807.72 |
| Revenue Next Year | $5.36 | $172.52 |
| P/E Ratio | $26.64 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $34.10 | $44.12 |
| 52 Week High | $49.62 | $78.48 |
| Indicator | UBSI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 65.62 |
| Support Level | $47.69 | $49.36 |
| Resistance Level | $48.22 | $60.10 |
| Average True Range (ATR) | 0.65 | 1.95 |
| MACD | -0.14 | 0.61 |
| Stochastic Oscillator | 19.90 | 91.55 |
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which offers a full range-of-products and services through various delivery channels. Included among the banking products and services offered are the acceptance of deposits in checking, savings, time, and money market accounts; the making and servicing of personal, credit card, commercial, and floor plan loans; and the making of construction and real estate loans, as well as the origination and sale of residential mortgages in the secondary market. Also offered are trust and brokerage services, safe deposit boxes, and wire transfers.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.